Statin myotoxicity: A review of genetic susceptibility factors
Authors:
- 1 January 2014
- journal article
- review article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 24 (1) , 4-15
Abstract
No abstract availableKeywords
This publication has 134 references indexed in Scilit:
- The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced MyopathyClinical Pharmacology & Therapeutics, 2012
- Mechanisms of statin-induced myalgia assessed by physiogenomic associationsAtherosclerosis, 2011
- Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathiesMolecular Genetics and Metabolism, 2011
- Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS StudyClinical Pharmacology & Therapeutics, 2010
- Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyArthritis & Rheumatism, 2010
- Expectations, validity, and reality in pharmacogeneticsJournal of Clinical Epidemiology, 2010
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJACC, 2009
- Mutations in LPIN1 Cause Recurrent Acute Myoglobinuria in ChildhoodThe American Journal of Human Genetics, 2008
- The Role of Coenzyme Q10 in Statin-Associated MyopathyJACC, 2007
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002